Synthetic solutions for immuno-oncology
How Synthorx is harnessing synthetic DNA to enhance biologics
Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is building a pipeline of cytokines with tailored pharmacology, and plans to expand to other modifications and other modalities.
Fresh off a December IPO that raised $150.7 million on NASDAQ, Synthorx is lining up a suite of preclinical candidates, starting with its IL-2 immuno-oncology program THOR-707. The compound is slated for IND submission next quarter, and the company expects Phase I/II data within 12 months. ...